COVID-19 drug remdesivir will be available for coronavirus patients this week, Gilead Sciences' CEO said Sunday — and the company is donating the entire supply.
Gilead CEO Daniel O'Day told CBS' "Face of the Nation":
"We intend to get [remdesivir] to patients in the early part of this next week, beginning to work with the government which will determine which cities are most vulnerable and where the patients are that need this medicine.
We've donated the entire supply that we have within our supply chain and we did that because we acknowledge and recognize the human suffering, the human need here, and want to make sure nothing gets in the way of this getting to patients."
Preliminary clinical trial results released last week showed at least 50% of the COVID-19 patients treated with a five-day dosage of remdesivir improved. The National Institute of Allergy and Infectious Diseases then released a study that showed infected patients who took the remdesivir usually recovered after 11 days — four days faster than those who didn't take the drug.
Following these successful trials, the FDA granted emergency authorization for the drug to be used to treat coronavirus.
Gilead projects that it can make 1 million rounds of its 10-day treatment regimen of the drug by the end of this year.